JAZZN Stock Chart & Stats
$2985.00
$0.00(0.00%)
At close: 4:00 PM EDT
$2985.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$2,135.00 - $3,120.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$270.76B
Enterprise Value$18.93K
Total Cash (Recent Filing)$2.20B
Total Debt (Recent Filing)$4.41B
Price to Earnings (P/E)16.2
Beta-0.45
Next Earnings
Nov 11, 2026EPS Estimate
109.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)15.20
Shares Outstanding64,914,570
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)2.40
Price to Sales (P/S)2.43
P/FCF Ratio9.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$4,937.85Price Target Upside65.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)424.82
Revenue Forecast (FY)$80.19B
Bulls Say, Bears Say
Bulls Say
Broad Product-led GrowthBroad-based growth across sleep and oncology products supports a durable expansion in Jazz’s commercial platform. Higher guidance, strong patient additions, and double-digit brand growth indicate improving demand and provide resources to reinvest in launches, lifecycle management, and pipeline development.
Strong Cash GenerationConsistently positive operating and free cash flow gives Jazz meaningful internal funding capacity for clinical development, business development, debt management, and commercialization. The substantial cash balance also improves resilience while the company expands its oncology and rare-neurology portfolio.
Ziihera Regulatory ExpansionThe FDA approval materially broadens Ziihera’s commercial opportunity and strengthens Jazz’s oncology position in a serious, high-need disease. Statistically significant and clinically meaningful overall-survival improvement supports treatment adoption and creates a durable growth avenue beyond existing products.
Bears Say
Uneven Earnings HistoryRecent profitability and healthy margins are encouraging, but repeated historical losses show that earnings conversion has not been consistently stable. This volatility can complicate long-term planning and makes future results more dependent on sustained product execution and successful pipeline investments.
Oxybate Competitive RiskThe oxybate franchise is an important sleep-medicine revenue base, so generic entry and emerging orexin alternatives could pressure patient retention, pricing, or growth over time. Limited generic uptake so far does not remove the need to defend the franchise through differentiation and continued innovation.
Margin And Investment PressureHigher royalties on growing products and rapid increases in commercial and clinical spending can limit operating leverage even when revenue expands. These costs may be strategically justified, but sustained expense growth raises the execution burden required to translate product momentum into durable profit growth.
Jazz Pharmaceuticals News
JAZZN FAQ
What was Jazz Pharmaceuticals’s price range in the past 12 months?
Jazz Pharmaceuticals lowest stock price was $2135.00 and its highest was $3120.00 in the past 12 months.
What is Jazz Pharmaceuticals’s market cap?
Jazz Pharmaceuticals’s market cap is $270.76B.
When is Jazz Pharmaceuticals’s upcoming earnings report date?
Jazz Pharmaceuticals’s upcoming earnings report date is Nov 11, 2026 which is in 64 days.
How were Jazz Pharmaceuticals’s earnings last quarter?
Jazz Pharmaceuticals released its earnings results on Aug 03, 2026. The company reported $96.875 earnings per share for the quarter, missing the consensus estimate of $104.764 by -$7.889.
Is Jazz Pharmaceuticals overvalued?
According to Wall Street analysts Jazz Pharmaceuticals’s price is currently Undervalued.
Does Jazz Pharmaceuticals pay dividends?
Jazz Pharmaceuticals does not currently pay dividends.
What is Jazz Pharmaceuticals’s EPS estimate?
Jazz Pharmaceuticals’s EPS estimate is 109.65.
How many shares outstanding does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals has 64,914,570 shares outstanding.
What happened to Jazz Pharmaceuticals’s price movement after its last earnings report?
Jazz Pharmaceuticals reported an EPS of $96.875 in its last earnings report, missing expectations of $104.764. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Jazz Pharmaceuticals?
Currently, no hedge funds are holding shares in MX:JAZZN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jazz Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4,937.85 (65.42% Upside)
$4,937.85 (65.42% Upside)
Blogger Sentiment
Bullish
MX:JAZZN Sentiment 70%
Sector Average 60%
Sector Average 60%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
92.79%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Jazz Pharmaceuticals
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
JAZZN Company Deck
JAZZN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong commercial and pipeline wins — record revenue, raised guidance, double-digit growth across key brands (oncology +32%, Xywav +13%, Epidiolex +16%, Zepzelca +42%) and a solid balance sheet — while acknowledging manageable margin pressure from royalties, rising SG&A/R&D investments, label adjustments for Zepzelca second-line, and potential future competitive/generic risks for the oxybate franchise. On balance, the positive execution, guidance raise, cash generation and late-stage regulatory momentum outweigh the identified challenges.View all MX:JAZZN earnings summariesJAZZN Stock 12 Month Forecast
Average Price Target
$4,937.85
▲(65.42% Upside)
Technical Analysis
Neurocrine
―
Xenon
―
Axsome Therapeutics
―
Harmony Biosciences Holdings
―
Praxis Precision Medicines
―